Lymphoma adverse event reports that record this term

Kind of term: MedDRA preferred term
Plain meaning: a cancer of the lymphatic system

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 15,270 adverse event reports that record the MedDRA preferred term Lymphoma. In plain words, the term means: a cancer of the lymphatic system. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 727 reports in the 12 months to June 2026 and 713 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 774 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 727 (0.1%) record this term. Reports for female patients were 43.3% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Plain meaning

A cancer of the lymphatic system. The words are from the fixed dictionary of this site. They add nothing to a report.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 132 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Lymphoma name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	62
Acetaminophen		27
Aclasta		25
Actemra	Interleukin-6 receptor antagonist	154
Adalimumab	Tumor necrosis factor blocker	68
Apixaban	Factor Xa inhibitor	32
Apo Leflunomide		38
Apo-Leflunomide		74
Arava	Antirheumatic agent	75
Avonex	Interferon beta	115
Azathioprine	Purine antimetabolite	100
Bendamustine		336
Bendamustine hydrochloride	Alkylating drug	68
Carboplatin	Platinum-based drug	97
Carmustine	Alkylating drug	29
Celebrex	Nonsteroidal anti-inflammatory drug	36
CellCept	Antimetabolite immunosuppressant	34
Certolizumab pegol	Tumor necrosis factor blocker	45
Cimzia	Tumor necrosis factor blocker	78
Cisplatin	Platinum-based drug	215
Clozapine	Atypical antipsychotic	58
Clozaril	Atypical antipsychotic	192
Copaxone		59
Cosentyx	Interleukin-17A antagonist	141
Crestor	HMG-CoA reductase inhibitor	25
Cyclophosphamide	Alkylating drug	758
Cyclophosphamide Doxorubicin Prednisone Vincristine		131
Cyclosporine	Calcineurin inhibitor immunosuppressant	71
Cytarabine	Nucleoside metabolic inhibitor	270
Dexamethasone	Corticosteroid	293
Doxorubicin	Anthracycline topoisomerase inhibitor	300
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	150
Dupixent	Interleukin-4 receptor alpha antagonist	143
Eliquis	Factor Xa inhibitor	52
Enbrel	Tumor necrosis factor blocker	1,030
Entresto	Angiotensin 2 receptor blocker	37
Entyvio	Integrin receptor antagonist	43
Epirubicin		50
Etanercept	Tumor necrosis factor blocker	73
Etoposide	Topoisomerase inhibitor	262
Fludarabine	Nucleoside metabolic inhibitor	193
Forteo	Parathyroid hormone analog	73
Gemcitabine	Nucleoside metabolic inhibitor	195
Gilenya	Sphingosine 1-phosphate receptor modulator	40
Hizentra	Human immunoglobulin G	30
Humalog	Insulin analog	44
Human immunoglobulin g	Human immunoglobulin G	84
Human Immunoglobulin G Hyaluronidase Recombinant Human		30
Humira		1,183
Hydroxychloroquine	Antimalarial	128
Hydroxychloroquine sulfate	Antimalarial	125
Ibrutinib (form s4)	Kinase inhibitor	61
Idelalisib	Kinase inhibitor	44
Ifosfamide	Alkylating drug	109
Imbruvica	Kinase inhibitor	198
Inflectra	Tumor necrosis factor blocker	31
Infliximab	Tumor necrosis factor blocker	103
Infliximab Recombinant		33
Irbesartan	Angiotensin 2 receptor blocker	36
Jakafi	Janus kinase inhibitor	32
Kaletra	Cytochrome P450 3A inhibitor	26
Keytruda	Programmed death Receptor-1 blocking antibody	25
Leflunomide	Antirheumatic agent	126
Lenalidomide	Thalidomide analog	274
Mabthera		179
Melphalan	Alkylating drug	50
Methotrexate	Folate analog metabolic inhibitor	788
Methotrexate sodium	Folate analog metabolic inhibitor	144
Methylprednisolone	Corticosteroid	43
Mitoxantrone	Topoisomerase inhibitor	30
Mycophenolate mofetil	Antimetabolite immunosuppressant	109
Neoral	Calcineurin inhibitor immunosuppressant	42
Neulasta	Leukocyte growth factor	26
Nexium	Proton pump inhibitor	60
Norvir	Cytochrome P450 3A inhibitor	35
Nplate	Thrombopoietin receptor agonist	49
Nucala	Interleukin-5 antagonist	31
Obinutuzumab	CD20-directed cytolytic antibody	96
Olanzapine	Atypical antipsychotic	39
Oncovin		37
Orencia	Selective T cell costimulation modulator	290
Otezla	Phosphodiesterase 4 inhibitor	65
Oxaliplatin	Platinum-based drug	129
Pantoprazole	Proton pump inhibitor	29
Plaquenil	Antimalarial	33
Polatuzumab vedotin		284
Polivy		95
Pradaxa	Direct thrombin inhibitor	31
Prednisolone	Corticosteroid	208
Prednisone	Corticosteroid	605
Prograf	Calcineurin inhibitor immunosuppressant	84
Prolia	RANK ligand inhibitor	85
Ranitidine	Histamine-2 receptor antagonist	586
Ranitidine hydrochloride	Histamine-2 receptor antagonist	234
Rebif	Interferon beta	47
Remicade	Tumor necrosis factor blocker	1,001
Revlimid	Thalidomide analog	437
Rheumatrex		91
Ribavirin	Nucleoside analog antiviral	51
Rinvoq	Janus kinase inhibitor	107
Rituxan	CD20-directed cytolytic antibody	307
Rituximab	CD20-directed cytolytic antibody	1,006
Simponi	Tumor necrosis factor blocker	159
Skyrizi	Interleukin-23 antagonist	136
Soliris	Complement inhibitor	30
Stelara	Interleukin-12 antagonist	121
Sulfasalazine	Aminosalicylate	181
Tacrolimus	Calcineurin inhibitor immunosuppressant	104
Tafasitamab		69
Tafasitamab-cxix		157
Taltz	Interleukin-17A antagonist	25
Tecfidera		55
Thiotepa	Alkylating drug	25
Tiotropium bromide	Anticholinergic	67
Tivicay	Human immunodeficiency virus integrase strand transfer inhibitor	27
Trulicity	GLP-1 receptor agonist	26
Truvada	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	41
Truxima	CD20-directed cytolytic antibody	31
Tysabri	Integrin receptor antagonist	83
Valsartan	Angiotensin 2 receptor blocker	37
Vedolizumab	Integrin receptor antagonist	78
Venclexta	BCL-2 inhibitor	108
Venetoclax	BCL-2 inhibitor	103
Vincristine		411
Vincristine sulfate	Vinca alkaloid	74
Xarelto	Factor Xa inhibitor	27
Xeljanz	Janus kinase inhibitor	179
Xolair	Anti-IgE	70
Yescarta	CD19-directed chimeric antigen receptor	49
Zantac		935
Zometa		36
Zostavax		81

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 53 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Lymphoma name, in order of name
Class	Reports with this term
Alkylating drug	1,057
Aminosalicylate	192
Angiotensin 2 receptor blocker	151
Anthracycline topoisomerase inhibitor	456
Anti-IgE	86
Anticholinergic	86
Antimalarial	290
Antimetabolite immunosuppressant	149
Antirheumatic agent	201
Atypical antipsychotic	320
BCL-2 inhibitor	211
Calcineurin inhibitor immunosuppressant	315
CD19-directed chimeric antigen receptor	88
CD20-directed cytolytic antibody	1,485
Corticosteroid	1,213
Cytochrome P450 3A inhibitor	85
Endothelin receptor antagonist	64
Factor Xa inhibitor	111
Folate analog metabolic inhibitor	932
GLP-1 receptor agonist	92
Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	91
Histamine-2 receptor antagonist	820
HMG-CoA reductase inhibitor	85
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	85
Human immunoglobulin G	131
Insulin analog	108
Integrin receptor antagonist	204
Interferon beta	168
Interleukin-12 antagonist	125
Interleukin-17A antagonist	172
Interleukin-23 antagonist	150
Interleukin-4 receptor alpha antagonist	151
Interleukin-6 receptor antagonist	194
Janus kinase inhibitor	359
Kinase inhibitor	493
Leukocyte growth factor	71
Nonsteroidal anti-inflammatory drug	66
Nucleoside analog antiviral	51
Nucleoside metabolic inhibitor	706
Parathyroid hormone analog	73
Phosphodiesterase 4 inhibitor	71
Platinum-based drug	441
Programmed death Receptor-1 blocking antibody	69
Proton pump inhibitor	157
Purine antimetabolite	114
RANK ligand inhibitor	92
Selective T cell costimulation modulator	352
Sphingosine 1-phosphate receptor modulator	64
Thalidomide analog	711
Thrombopoietin receptor agonist	78
Topoisomerase inhibitor	292
Tumor necrosis factor blocker	2,619
Vinca alkaloid	76

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Lymphoma, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Lymphoma
Age	Reports	Share
Under 2	12	0.1%
2 to 11	55	0.4%
12 to 17	95	0.6%
18 to 44	1,180	7.7%
45 to 64	3,287	21.5%
65 to 74	2,176	14.3%
75 and over	1,651	10.8%
Age not given	6,814	44.6%

Sex of the patient in the reports that record Lymphoma
Sex	Reports	Share
Female	6,614	43.3%
Male	6,529	42.8%
Unknown or not given	2,127	13.9%

Age and sex are as the report gives them. 48.9% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Lymphoma: adverse event reports that record this term. https://reportedreactions.com/reaction/lymphoma/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Lymphoma mean in an adverse event report?

In plain words: a cancer of the lymphatic system. It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page